RAINBOW

- Mr. Vikas Maheshwari has resigned as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of Rainbow Children's Medicare Limited. - His resignation is effective from the close of business hours on August 31, 2026, due to personal reasons. - The company has identified a prospective candidate for the CFO position.

- Rainbow Children's Medicare Limited completed the acquisition of 64% partnership interest and capital contribution in Super Prime Medical Care LLP on August 14, 2026.

- Q1 FY27 saw robust performance with operating revenue up 33% YoY to INR 470 crores, and EBITDA up 30% YoY to INR 134.6 crores, maintaining a healthy EBITDA margin of 28.6%. PAT increased by 16% YoY to INR 62.5 crores. Organic revenue growth was 24% YoY, with acquisitions contributing approximately INR 38 crores. - The company plans to add 2,500 beds over the next 5 years to expand its network capacity to 5,000 beds, with an estimated capex of INR 2,200 crores, and has visibility on 1,200 beds currently under various stages of development. - Key expansion initiatives include a new 100-bed brownfield hospital in Malad, Mumbai (expected Q1 FY28), acquisition of a 70-bed hospital in Nellore (with a 30-bed maternal care block expected in 6 months), and a 50-bed hospital in Guntur (commencing operations in a couple of months). Operations in Indore hospital are expected to begin in Q3 FY27. - Management expects revenue growth in the 20% range for Q2 FY27, aims to cross INR 2,000 crores in revenue by the end of FY27, and projects the potential to double revenue over the subsequent four years. - EBITDA margins are expected to return to the 24%-25% range (pre-Ind AS basis) by the end of FY27, driven by maturing new hospitals and improved operating leverage. New Bengaluru hospitals, currently incurring losses, are expected to breakeven within 12-18 months. - The company is strengthening its digital and referral ecosystems to drive patient volumes and is actively working to reduce dependence on seasonality. ARPOB is expected to grow with increasing complexity of pediatric and maternity cases, with mature hospitals showing an 18% increase in ARPOB in Q1 FY27.

- Audio recording of the Earnings Conference Call for Q1 & FY27, held on July 31, 2026, to discuss the financial and operational performance for the quarter ended June 30, 2026, is available on the company's website.

- Consolidated Revenue ₹4,700Mn vs ₹3,529Mn (▲33.2% YoY) - EBITDA ₹1,346Mn vs ₹1,036Mn (▲29.9% YoY) - PAT ₹625Mn vs ₹538Mn (▲16.2% YoY) - EBITDA Margin 28.6% vs 29.4% (▼71bps) - Company to enter Mumbai with a 100-bed hospital (expected Q1 FY28). - Strengthened Andhra Pradesh footprint with acquisition of a 70-bed hospital in Nellore and a 50-bed hospital in Guntur.

- Rainbow Children's Medicare Limited submitted an Earnings Presentation for Q1 FY26-27 (quarter ended June 30, 2026) to exchanges.- The presentation highlights multiple JCI re-accreditations for its hospitals and fertility centers.

- Rainbow Children's Medicare Limited granted 2,570 Stock Options to Mr. Anshuman Jaiswal under ESOP 2025 on July 30, 2026. - The options are exercisable at a discount of not more than 20% on the July 29, 2026 closing price on NSE.

- Consolidated Revenue ₹470.00 Cr vs ₹352.93 Cr (▲33.2% YoY) - EBITDA ₹134.65 Cr vs ₹103.62 Cr (▲29.9% YoY) - PAT (attributable to Owners) ₹60.57 Cr vs ₹53.50 Cr (▲13.2% YoY) - EBITDA Margin 28.65% vs 29.36% (▼71bps) - Board approved the elevation of Mr. Anshuman Jaiswal as Chief Legal Officer and Senior Management Personnel (SMP). - The company plans capacity addition for a new hospital in Malad, Mumbai, and acquisition of 64% partnership interest in a hospital in Nellore, Andhra Pradesh, both expected to be completed by Q2 FY27.

- Consolidated Revenue ₹469.98Cr vs ₹352.93Cr (▲33.2% YoY) - EBITDA ₹134.65Cr vs ₹103.62Cr (▲30.0% YoY) - PAT ₹62.54Cr vs ₹53.81Cr (▲16.2% YoY) - EBITDA Margin 28.65% vs 29.36% (▼71bps) - Mr. Anshuman Jaiswal elevated to Chief Legal Officer and designated as Senior Management Personnel (SMP) on July 30, 2026.

- Consolidated Revenue ₹4,699.85Mn vs ₹3,529.29Mn (▲33.17% YoY) - EBITDA ₹1,346.45Mn vs ₹1,036.23Mn (▲30.07% YoY) - PAT ₹605.72Mn vs ₹534.99Mn (▲13.22% YoY) - EBITDA Margin 28.65% vs 29.36% (▼71bps) - Mr. Anshuman Jaiswal elevated from Group Head – Legal to Chief Legal Officer and designated as Senior Management Personnel (SMP).

- Strategic initiative to establish a women's and children's hospital in Guntur, Andhra Pradesh, adding 50 beds. - Expected to be commissioned by September 2026. - Investment required is approximately ₹15 Crore, financed through Internal Accruals.

- Rainbow Children's Medicare Limited will acquire a 64% partnership interest in Super Prime Medical Care LLP for ₹19.84 Cr. - The LLP operates a 70-bed children's hospital in Nellore, Andhra Pradesh. - The acquisition, expected by August 31, 2026, aims to strengthen the company's regional network and increase capacity by 70 beds, with plans to add 30 more.

- Rainbow Children's Medicare Limited is acquiring a 64% partnership interest in Super Prime Medical Care LLP for ₹19.84 Cr in cash, funded by internal accruals. - The acquisition is for a 70-bed children's hospital in Nellore, Andhra Pradesh, and is expected to be completed by August 31, 2026. - This expansion will strengthen the company's hub-and-spoke model, enhance specialized care across Andhra Pradesh, and add 70 beds to its network. - Super Prime Medical Care LLP's unaudited provisional turnover for FY 2025-26 was ₹9.44 Crore.

- Rainbow Children's Medicare Limited (RCML) is developing a new 100-bed children's and women's hospital in Malad, Mumbai, through its subsidiary, Rainbow Women & Children's Hospital Private Limited (RWCHPL). - The estimated project cost is ₹90 Crore, with RCML contributing approximately ₹68.40 Crore. - Fountainhead TCHM Healthcare LLP will acquire a 24% equity stake in RWCHPL, making it a subsidiary with RCML holding 76% and retaining control. - The new hospital is expected to be commissioned by Q1 FY27-28, expanding the company's healthcare network in Maharashtra.

- Rainbow Children's Medicare Limited announced the development of a new 100-bed children's and women's hospital at Malad, Mumbai through its subsidiary RWCHPL. - The project involves an estimated cost of approximately ₹90 Crore and is expected to be commissioned by Q1 FY27-28. - Fountainhead TCHM Healthcare LLP will acquire a 24% equity stake in RWCHPL for ₹24,000, with RCML retaining 76% control. - This expansion aims to enhance specialized pediatric, women, and neonatal care across Maharashtra.

- Rainbow Children's Medicare Limited is developing a new 100-bed children's and women's hospital at Malad, Mumbai, through its subsidiary, Rainbow Women & Children's Hospital Private Limited (RWCHPL). - The estimated project cost for this capacity addition is approximately ₹90 Crore. - The new hospital is expected to be commissioned by Q1 FY27-28. - Fountainhead TCHM Healthcare LLP will acquire a 24% equity stake in RWCHPL for ₹24,000, with RCML retaining 76% control. - This expansion aims to augment the company's healthcare delivery network and operational capacity in Maharashtra.

- The 28th AGM of Rainbow Children's Medicare Ltd on July 29, 2026, approved all resolutions. - Key approvals included the adoption of FY26 financials, a ₹3.5/- per Equity Share dividend, and re-appointments of Dr. Adarsh Kancharla, Dr. Ramesh Kancharla (CMD), and Dr. Dinesh Kumar Chirla (WTD).

- The 28th Annual General Meeting (AGM) of Rainbow Children's Medicare Limited was held on July 29, 2026. - Shareholders approved the Audited Standalone and Consolidated Financial Statements for FY ended March 31, 2026. - A dividend of ₹3.5/- per Equity Share was declared for the Financial Year ended March 31, 2026. - The re-appointment of several directors, including the Chairman & Managing Director, Whole-time Director, and Independent Directors, was approved.

- Concall Schedule - Concall Date: Friday, July 31, 2026 - Concall Time: 10:00 AM (IST) - Purpose: To discuss the financial and operating performance for the quarter ended June 30, 2026 (Q1 & FY 2026-27).

- Rainbow Children's Medicare received an overall ESG rating of 61 and Core ESG rating of 73 from CRISIL ESG for FY 2025-26. - This reflects an improvement from "Adequate" to "Strong" ESG rating for FY 2024-25 and FY 2023-24. - The report was independently prepared by CRISIL ESG based on public disclosures.

- Intimation regarding the Integrated Annual Report for Financial Year 2025-26 as per SEBI Listing Regulations. - The report has been emailed to registered shareholders. - A web link and QR code are provided for others to access the Annual Report.

- Filing of the Business Responsibility and Sustainability Report (BRSR) for FY 2026. - Includes Independent Practitioners' Reasonable Assurance Report. - Highlights commitment to ESG principles, sustainability, and responsible business conduct. - No fines or penalties reported for the financial year.

- Consolidated Revenue ₹1,703.1 Cr vs ₹1,515.2 Cr (▲12.4% YoY) - EBITDA ₹544.2 Cr vs ₹489.8 Cr (▲11.1% YoY) - PAT ₹281.5 Cr vs ₹244.1 Cr (▲15.3% YoY) - EBITDA Margin 31.95% vs 32.32% (▼37bps) - The 28th Annual General Meeting (AGM) for FY 2026 will be held on Wednesday, July 29, 2026, at 10:00 A.M. (IST) via Video Conferencing/OAVM.

- Trading window for Designated Persons and their immediate relatives will close from July 1, 2026. - It will re-open 48 hours after the declaration of Unaudited Financial Results for the quarter ended June 30, 2026.

- Rainbow Children's Medicare Limited allotted 7,483 equity shares of ₹10 each on June 25, 2026. - The allotment is under the Employees Stock Unit Plan 2023, following the exercise of vested stock units. - The paid-up equity capital increased to ₹1,01,56,66,390.

- Allotment of 7,483 Equity Shares to one eligible employee under the Employees Stock Unit Plan 2023 on June 25, 2026. - Post-allotment, the paid-up equity share capital increased from ₹1,01,55,91,560 to ₹1,01,56,66,390.

- Concall discussed strong Q4 & FY26 financial results, highlighting highest-ever quarterly revenue and significant YoY growth in profitability, alongside a debt-free balance sheet and strong cash position. - Management guided for 20% revenue growth in FY27 while maintaining margins, with the fertility business (IVF) projected to grow ~25% YoY for the next three years. - Mature hospitals are expected to achieve ~60% occupancy, and Average Revenue Per Patient (ARPP) is anticipated to grow 5-6% annually. - Current development pipeline includes ~900 beds, with estimated capex of INR 400-500 Cr for Gurugram and INR 300-350 Cr for other projects over the next two years, fully funded by internal accruals. - Strategic focus areas include improving operational efficiency, patient experience, strengthening clinical offerings, and evaluating M&A opportunities.

Rainbow Children's Medicare Limited announced the availability of the audio recording of its conference call with investors/analysts held on May 25, 2026, at 10:00 AM (IST). The call discussed the financial and operational performance for the quarter and financial year ended March 31, 2026. The recording is accessible on the company's website.

The Board of Directors of Rainbow Children's Medicare Limited, in a meeting on May 23, 2026, approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The Board recommended a final dividend of ₹3.5/- per Equity Share for FY 2025-26, subject to shareholder approval. Additionally, the Board approved the re-appointment of Dr. Ramesh Kancharla as Chairman & MD, Dr. Dinesh Kumar Chirla as Whole Time Director, and Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati as Independent Directors for five-year terms. M/s. Lavanya & Associates LLP were re-appointed as Cost Auditors for FY 2026-27.

The Board of Directors of Rainbow Children's Medicare Limited, in its meeting on May 23, 2026, approved the audited financial results for Q4 and FY ended March 31, 2026, with an unmodified audit opinion. The Board recommended a final dividend of ₹3.5/- per equity share for FY26, subject to shareholder approval at the 28th AGM on July 29, 2026, with July 21, 2026, as the record date. Additionally, the re-appointments of the Chairman & MD, Whole Time Director, two Independent Directors, and Cost Auditors were approved.

Rainbow Children's Medicare Limited's Board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, with an unmodified audit opinion. The Board recommended a final dividend of ₹3.5/- per Equity Share for FY 2025-26. Additionally, the re-appointment of Dr. Ramesh Kancharla as Chairman and Managing Director, Dr. Dinesh Kumar Chirla as Whole Time Director, Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati as Independent Directors, and M/s. Lavanya & Associates LLP as Cost Auditors were approved, subject to shareholder consent.

Rainbow Children's Medicare Limited's Board of Directors, in its meeting on May 23, 2026, approved the audited financial results for the quarter and financial year ended March 31, 2026, with an unmodified audit opinion. The Board recommended a final dividend of ₹3.5/- per equity share for FY26, subject to AGM approval. Additionally, the re-appointment of Dr. Ramesh Kancharla as Chairman & MD, Dr. Dinesh Kumar Chirla as Whole Time Director, and two Independent Directors (Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati) for five-year terms was approved. M/s. Lavanya & Associates LLP were re-appointed as Cost Auditors for FY26-27.

The Board of Directors of Rainbow Children's Medicare Limited, in a meeting on May 23, 2026, approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. A final dividend of ₹3.50 per equity share for FY 2025-26 was recommended, subject to shareholder approval at the 28th Annual General Meeting on July 29, 2026. The Board also approved the re-appointment of Dr. Ramesh Kancharla as Chairman & MD, Dr. Dinesh Kumar Chirla as Whole Time Director, Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati as Independent Directors, and M/s. Lavanya & Associates LLP as Cost Auditors for their respective terms.

On May 23, 2026, Rainbow Children's Medicare Limited's Nomination and Remuneration Committee granted 2,67,550 Stock Options under its ESOP Scheme 2025 to eligible employees. These options are exercisable into an equal number of equity shares, with an exercise price discounted by up to 20% from the previous day's NSE closing price. The options vest over a minimum of 1 year and are exercisable within two years from vesting.

Consolidated Revenue ₹459.9Cr vs ₹370.1Cr (▲24.3% YoY), EBITDA ₹144.7Cr vs ₹114.7Cr (▲26.1% YoY), PAT ₹78.2Cr vs ₹56.6Cr (▲38.3% YoY). EBITDA Margin 31.5% vs 31.0% (▲47bps).

Standalone Revenue ₹4,080.64 Mn vs ₹3,539.95 Mn (▲15.28% YoY), EBITDA ₹1,273.97 Mn vs ₹1,108.14 Mn (▲14.96% YoY), PAT ₹593.05 Mn vs ₹545.40 Mn (▲8.74% YoY). EBITDA Margin 31.22% vs 31.30% (▼8bps). The Board also recommended a final dividend of ₹3.5/- per Equity Share for FY26.

The Board of Directors of Rainbow Children's Medicare Limited approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, with an unmodified audit opinion. A final dividend of ₹3.5/- per equity share was recommended for FY 2025-26. The Board also approved the re-appointment of Dr. Ramesh Kancharla as CMD, Dr. Dinesh Kumar Chirla as WTD, and Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati as Independent Directors for five-year terms. The 28th Annual General Meeting is scheduled for July 29, 2026.

Consolidated Revenue ₹459.90 Cr vs ₹370.11 Cr (▲24.3% YoY), EBITDA ₹143.16 Cr vs ₹114.73 Cr (▲24.8% YoY), PAT ₹78.22 Cr vs ₹56.55 Cr (▲38.3% YoY). EBITDA Margin 31.13% vs 30.99% (▲14bps). The Board also recommended a final dividend of ₹3.50 per equity share for FY 2025-26, and approved the re-appointment of key managerial personnel and independent directors.

Rainbow Children's Medicare Limited announced an Earnings Conference Call for Investors/Analysts on May 25, 2026, at 10:00 AM (IST). The call will discuss the financial and operating performance for the quarter and financial year ended March 31, 2026.

Rainbow Children's Medicare Limited announced that its appeal against a GST demand notice (under Section 74(5) of CGST Act, 2017) has been disallowed, and the original demand upheld by the Principal Commissioner of Customs and Central Tax (Appeals-1) on May 7, 2026. The company states there is no material impact on its financial position or operations at this stage and no payment has been made yet. The company is in the process of preferring a further appeal.

Rainbow Children's Medicare Limited announced the commencement of a new 60-bed spoke hospital in HRBR Layout and an IVF centre in Mahadevapura, Bengaluru, operational from May 4, 2026. The expansion, funded by internal accruals with a total investment of approximately ₹52 crore, increases the company's total bed capacity to ~2,435. This move strengthens its presence in high-growth micro-markets and enhances access to integrated pediatric, obstetric, and fertility services.